AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that. The clinical ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...